A novel platform for attenuating immune hyperactivity using EXO‐CD24 in COVID‐19 and beyond

A novel platform for attenuating immune hyperactivity using EXO‐CD24 in COVID‐19 and beyond

Abstract A small but significant proportion of COVID‐19 patients develop life‐threatening cytokine storm. We have developed a new anti‐inflammatory drug, EXO‐CD24, a combination of an immune checkpoint (CD24) and a delivery platform (exosomes). CD24 inhibits the NF‐kB pathway and the production of c...

Full description

Bibliographic Details
Main Authors: Shiran Shapira, Marina Ben Shimon, Mori Hay‐Levi, Gil Shenberg, Guy Choshen, Lian Bannon, Michael Tepper, Dina Kazanov, Jonathan Seni, Shahar Lev‐Ari, Michael Peer, Dimitrios Boubas, Justin Stebbing, Sotirios Tsiodras, Nadir Arber
Format: Article
Language:English
Published: Springer Nature 2022-07-01
Series:EMBO Molecular Medicine
Subjects:
CD24
COVID‐19
cytokine storm
exosomes
EXO‐CD24
Online Access:https://doi.org/10.15252/emmm.202215997

Internet

https://doi.org/10.15252/emmm.202215997

Similar Items